000165820 001__ 165820
000165820 005__ 20240229123210.0
000165820 0247_ $$2doi$$a10.1186/s12916-020-01772-x
000165820 0247_ $$2pmid$$apmid:33148280
000165820 0247_ $$2pmc$$apmc:PMC7643418
000165820 0247_ $$2altmetric$$aaltmetric:93746978
000165820 037__ $$aDKFZ-2020-02400
000165820 041__ $$aeng
000165820 082__ $$a610
000165820 1001_ $$0P:(DE-He78)ef3f7c40c2c68936a43baab29d559371$$aMukama, Trasias$$b0$$eFirst author$$udkfz
000165820 245__ $$aRisk of invasive breast cancer in relatives of patients with breast carcinoma in situ: a prospective cohort study.
000165820 260__ $$aHeidelberg [u.a.]$$bSpringer$$c2020
000165820 3367_ $$2DRIVER$$aarticle
000165820 3367_ $$2DataCite$$aOutput Types/Journal article
000165820 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1604917566_25264
000165820 3367_ $$2BibTeX$$aARTICLE
000165820 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000165820 3367_ $$00$$2EndNote$$aJournal Article
000165820 500__ $$a#EA:C120#LA:C120#
000165820 520__ $$aWide implementation of mammography screening has resulted in increased numbers of women diagnosed with breast carcinoma in situ. We aimed to determine the risk of invasive breast cancer in relatives of patients with breast carcinoma in situ in comparison to the risk in relatives of patients with invasive breast cancer.We analyzed the occurrence of cancer in a nationwide cohort including all 5,099,172 Swedish women born after 1931 with at least one known first-degree relative. This was a record linkage study of Swedish family cancer datasets, including cancer registry data collected from January 1, 1958, to December 31, 2015. We calculated standardized incidence ratios (SIRs) and 10-year cumulative risk of breast cancer diagnosis for women with a family history of in situ and invasive breast cancer.Having one first-degree relative with breast carcinoma in situ was associated with 50% increased risk of invasive breast cancer (SIR = 1.5, 95% CI 1.4-1.7) when compared to those who had no family history of invasive breast cancer or breast carcinoma in situ in either first- or second-degree relatives. Similarly, having one first-degree relative with invasive breast cancer was associated with 70% (1.7, 1.7-1.8) increased risk. The 10-year cumulative risk for women at age 50 with a relative with breast carcinoma in situ was 3.5% (2.9-3.9%) and was not significantly different from 3.7% (3.6-3.8%) risk for 50-year-old women with a relative with invasive breast cancer (95% confidence intervals overlapped).The risk of invasive breast cancer for women with a family history of breast carcinoma in situ was comparable to that for women with a family history of invasive breast cancer. Therefore, family history of breast carcinoma in situ should not be overlooked in recommendations for breast cancer prevention for women with a family history of breast cancer.
000165820 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000165820 588__ $$aDataset connected to CrossRef, PubMed,
000165820 7001_ $$0P:(DE-He78)b510b884502b619724039bf33fdae68a$$aFallah, Mahdi$$b1$$udkfz
000165820 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b2$$udkfz
000165820 7001_ $$0P:(DE-He78)62b0f1b5eccef2b5f2e55b7f13ccde6d$$aXu, Xing$$b3$$udkfz
000165820 7001_ $$aSundquist, Kristina$$b4
000165820 7001_ $$aSundquist, Jan$$b5
000165820 7001_ $$0P:(DE-He78)e56510c7dedbff7a279ad76dad80eeda$$aKharazmi, Elhamalsadat$$b6$$eLast author$$udkfz
000165820 773__ $$0PERI:(DE-600)2131669-7$$a10.1186/s12916-020-01772-x$$gVol. 18, no. 1, p. 295$$n1$$p295$$tBMC medicine$$v18$$x1741-7015$$y2020
000165820 909CO $$ooai:inrepo02.dkfz.de:165820$$pVDB
000165820 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ef3f7c40c2c68936a43baab29d559371$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000165820 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b510b884502b619724039bf33fdae68a$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000165820 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000165820 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)62b0f1b5eccef2b5f2e55b7f13ccde6d$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000165820 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e56510c7dedbff7a279ad76dad80eeda$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000165820 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000165820 9141_ $$y2020
000165820 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBMC MED : 2018$$d2020-09-05
000165820 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-09-05
000165820 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-09-05
000165820 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-09-05
000165820 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2020-09-05
000165820 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2020-09-05
000165820 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Open peer review$$d2020-09-05
000165820 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2020-09-05
000165820 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-09-05
000165820 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-09-05
000165820 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-09-05
000165820 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-09-05
000165820 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-09-05
000165820 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-09-05
000165820 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-09-05
000165820 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-09-05
000165820 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-09-05
000165820 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBMC MED : 2018$$d2020-09-05
000165820 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2020-09-05
000165820 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-09-05
000165820 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x0
000165820 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x1
000165820 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000165820 980__ $$ajournal
000165820 980__ $$aVDB
000165820 980__ $$aI:(DE-He78)C120-20160331
000165820 980__ $$aI:(DE-He78)C070-20160331
000165820 980__ $$aI:(DE-He78)HD01-20160331
000165820 980__ $$aUNRESTRICTED